National Advisory Council Agenda

136th Meeting of the National Advisory Council on Drug Abuse

Virtual Meeting – September 10, 2020

Closed Session

This meeting is closed to the public in accordance with the provisions set forth in section 552b{c}(4) and 552b{c}(6), Title 5, U.S. Code and section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2). 

11:00 a.m. Call to Order
Nora Volkow, M.D.
Director, NIDA


Review of Policy and Procedures
Susan Weiss, Ph.D.
Executive Secretary
National Advisory Council on Drug Abuse
Director, Division of Extramural Research, NIDA
11:15 a.m. Council Review of Grant Applications
Nora Volkow, M.D., Director, NIDA

Division of Therapeutics and Medical Consequences (DTMC)
Kurt Rasmussen, Ph.D., Director

Division of Neuroscience and Behavior (DNB)
Rita Valentino, Ph.D., Director

Division of Epidemiology, Services, and Prevention Research (DESPR)
Carlos Blanco, M.D., Ph.D., Director

Office of Translational Initiatives and Program Innovationa (OTIPI)
Elena Koustova, Ph.D., M.B.A., Director
12:15 a.m. Break

Videocast:

Members of the public who may wish to express views regarding any items discussed during this meeting may do so by writing Dr. Gillian Acca, within ten days of the meeting.  Any written statements by members of the public will receive careful consideration.

https://videocast.nih.gov/watch=38361

Open Session

12:45 p.m. Welcome and Opening Remarks
Nora Volkow, M.D. Director, NIDA
1:00 p.m. Director's Report
Nora Volkow, M.D. Director, NIDA
11:50 p.m. Discussion
Council Members
2:15 p.m. Points to Consider Updates
Susan Weiss, Ph.D.
Director, Division of Extramural Research
2:30 p.m. Racial Equity Action Plan
Gaya Dowling, Ph.D. and Emily Einstein Ph.D.
Racial Equity Co-Leads
2:50 p.m. Updates from DESPR
Carlos Blanco, M.D., Ph.D.
Director, DESPR
3:20 p.m. BRAIN Updates
John Ngai, Ph.D.
Director, BRAIN Initiative

3:50 p.m.

Concept Clearances​

  • Division of Therapeutics and Medical Consequences (DTMC)
    • In Vitro Metabolism and Non-Clinical ADME Studies – Jason Sousa, Ph.D., Health Scientist Administrator
    • Translational Avant-Garde – Iván Montoya, M.D., M.P.H., Deputy Director
  • Division of Neuroscience and Behavior (DNB)
    • Exploratory Studies to Understand Mechanisms of HIV Infection, Replication, Latency, and/or Pathogenesis (including HAND) in the Context of Substance Use and Substance Use Disorders (SUDs) – John Satterlee, Ph.D., Health Scientist Administrator
    • High-throughput Discovery and Validation of Novel Signal Transducers or Small Molecules that Modulate Opioid and other Substance Use Disorder-Relevant Pathways – John Satterlee, Ph.D., Health Scientist Administrator
    • Tools and Technologies to Explore Brain Biomolecular Condensates (BMCs) – John Satterlee, Ph.D., Health Scientist Administrator
    • Mechanistic Studies on the Impact of Social Inequality – Vani Pariyadath, Ph.D., Branch Chief
    • Sleep Disruption and the Impact on Substance Use Trajectory – Steve Grant, Ph.D., Health Scientist Administrator
  • Office of Translational Initiatives and Program Innovations (OTIPI)
    • Growing Great Ideas: Research Education Course in Product Development and Entrepreneurship for Life Science Researchers – Elena Koustova, Ph.D., M.B.A., Director, OTIPI
  • Division of Epidemiology, Services, and Prevention Research (DESPR)
    • Managing Comorbid Chronic Pain and OUD – Shelley Su, Ph.D., Health Scientist Administrator
  • AIDS Research Program (ARP)
    • Advancing Exceptional Research on HIV/AIDS and Substance Abuse – Vasundhara Varthakavi, D.V.M., Ph.D., Associate Director
    • HIV/AIDS High Priority Drug Abuse Research – Vasundhara Varthakavi, D.V.M., Ph.D., Associate Director
    • Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program – Vasundhara Varthakavi, D.V.M., Ph.D., Associate Director
4:15 p.m. Public Comments
Members of the public who may wish to express views regarding any items discussed during this meeting may do so by writing Dr. Gillian Acca, within ten days of the meeting.  Any written statements by members of the public will receive careful consideration.
4:30 p.m. Adjourn